CESAR MATOS-MARTINEZ: Open Payments
NPI 1639240575 · EDINBURG, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,551 in 98 payments from 11 companies in 2025. Trend: 2023 $202 · 2024 $692 · 2025 $1,551
Food & beverage: $1,551
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $243 |
| Otsuka America Pharmaceutical, Inc. | 15 | $227 |
| Lundbeck LLC | 10 | $221 |
| Teva Pharmaceuticals USA, Inc. | 10 | $186 |
| Alkermes, Inc. | 14 | $159 |
| ABBVIE INC. | 15 | $155 |
| E.R. Squibb & Sons, L.L.C. | 14 | $144 |
| Janssen Pharmaceuticals, Inc | 3 | $77 |
| Axsome Therapeutics, Inc. | 3 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $55 |
Products named: REXULTI, CAPLYTA, ARISTADA, VRAYLAR, COBENFY, AUSTEDO XR, UZEDY, Auvelity.
Industry payments across TX — which companies pay providers there.
